Dysport 500U — AbobotulinumtoxinA | FDA & EMA Approved | Ipsen

Dysport (AbobotulinumtoxinA) — The European-Origin Botulinum Toxin 
Standard for Aesthetic & Therapeutic Practice

Developed by Ipsen Biopharmaceuticals, one of the world's leading 
specialty pharmaceutical companies, Dysport (abobotulinumtoxinA) 
is a globally approved botulinum toxin type A with decades of 
clinical evidence across both aesthetic and therapeutic indications. 
FDA-approved since 2009, EMA-approved, and trusted by practitioners 
across more than 80 countries worldwide.

Dysport's abobotulinumtoxinA formulation is distinct from other 
botulinum toxin preparations — its unique diffusion profile and 
unit system are specific to Ipsen's proprietary assay method and 
are not interchangeable with any other botulinum toxin product.

──────────────────────────────────────
Product Specifications
──────────────────────────────────────

Product Name      : Dysport (AbobotulinumtoxinA)
Active Ingredient : AbobotulinumtoxinA (Clostridium botulinum
                    Toxin Type A, Hall Strain)
Available Strengths: 300 Units / 500 Units per vial
Composition       : AbobotulinumtoxinA + Human Serum Albumin
                    (125 mcg) + Lactose (2.5 mg)
Appearance        : Sterile lyophilized white powder
Preservative      : Preservative-free
Storage (Unrecon.): 2°C – 8°C, protect from light
Storage (Recon.)  : 2°C – 8°C, use within 24 hours
Country of Origin : Europe (Ipsen Biopharmaceuticals)
Manufacturer      : Ipsen Biopharmaceuticals
Certifications    : FDA (USA) · EMA (Europe) · GMP

⚠ Unit Note: Dysport units are specific to Ipsen's assay method.
  They are NOT interchangeable with units of any other botulinum
  toxin product including Botox, Nabota, or Xeomin.

──────────────────────────────────────
What is AbobotulinumtoxinA?
──────────────────────────────────────

Dysport contains abobotulinumtoxinA — a specific serotype of 
purified botulinum toxin type A complex derived from the Hall 
Strain of Clostridium botulinum. Its mechanism of action involves:

1. Heavy chain binding to presynaptic nerve terminal receptors
2. Receptor-mediated endocytosis into the nerve ending
3. Light chain cleavage of SNAP-25 protein
4. Blockade of acetylcholine release at the neuromuscular junction
5. Reversible local muscle relaxation

Compared to other botulinum toxin preparations, Dysport is 
known for its relatively wider diffusion radius — making it 
particularly suited for larger treatment areas such as the 
forehead, platysmal bands, and spasticity applications.

──────────────────────────────────────
Clinical Indications
──────────────────────────────────────

Aesthetic (FDA-Approved)
✔ Glabellar lines (frown lines) — 50 Units standard dose
✔ Forehead lines
✔ Crow's feet (lateral canthal lines)
✔ Platysmal bands (neck rejuvenation)
✔ Brow lifting
✔ Masseteric reduction (jawline slimming)

Therapeutic (FDA-Approved)
✔ Cervical dystonia — 500 Units initial dose
✔ Adult upper limb spasticity — 500–1,000 Units
✔ Adult lower limb spasticity — 1,000–1,500 Units
✔ Pediatric lower limb spasticity (≥2 years)
✔ Axillary hyperhidrosis

──────────────────────────────────────
Onset & Duration
──────────────────────────────────────

- Initial effect: 2–4 days post-injection
- Peak effect: 2–4 weeks
- Duration: 3–5 months (aesthetic indications)
- Retreatment interval: minimum every 3 months

──────────────────────────────────────
Reconstitution Guide
──────────────────────────────────────

300 Unit Vial
- 2.5 mL saline → 120 Units per 1.0 mL
- 3.0 mL saline → 100 Units per 1.0 mL

500 Unit Vial
- 1.0 mL saline → 500 Units per 1.0 mL
- 2.5 mL saline → 200 Units per 1.0 mL

Reconstitute with preservative-free 0.9% Sodium Chloride.
Swirl gently — do not shake. Use within 24 hours of reconstitution.
Single patient, single session use only.

──────────────────────────────────────
Dysport vs Nabota — Quick Reference
──────────────────────────────────────

                  Dysport             Nabota
Type              AbobotulinumtoxinA  OnabotulinumtoxinA
Origin            Europe (Ipsen)      Korea (Daewoong)
Units             Ipsen-specific      Daewoong-specific
Diffusion         Wider spread        More localized
Best For          Larger areas,       Precise focal
                  spasticity          treatment
FDA Approval      2009                2019 (as Jeuveau)
Strengths         300U / 500U         100U / 200U

──────────────────────────────────────
Safety & Compliance
──────────────────────────────────────

✔ FDA-approved (2009) · EMA-approved · GMP-manufactured
✔ Preservative-free — single-dose vials
✔ >80 countries global distribution
✔ Decades of clinical safety data across aesthetic & therapeutic use
✔ Cold-chain compliant shipping (2°C – 8°C maintained)

Contraindications: Known hypersensitivity to any botulinum toxin 
product or cow's milk protein. Infection at proposed injection site.
Not for use during pregnancy or lactation.

For use by licensed medical and aesthetic professionals only.
Dysport units are not interchangeable with any other botulinum 
toxin product. Refer to full prescribing information before use.